ArticleJournal of managed care & specialty pharmacy2026
Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) affects approximately 2.4 million people in the United States, with Kentucky having one of the highest HCV infection rates. The Centers for Disease Control and Prevention (CDC) recommend that all patients diagnosed with HCV be screened and vaccinated as appropriate for hepatitis A virus (HAV) and hepatitis B virus (HBV). Despite these long-standing recommendations, vaccination rates remain below target goals.
objectiveTo evaluate the impact of a pharmacist-led Medication Management Clinic (MMC) on HAV and HBV vaccination rates and other treatment outcomes in patients diagnosed with HCV compared with a traditional care model.
methodsThis retrospective cohort study compared patients diagnosed with HCV treated through a pharmacist-led MMC between August 1, 2022, and February 28, 2024, with those treated through traditional care between August 1, 2016, and February 28, 2018. Primary outcomes included HAV and HBV vaccination initiation rates among eligible patients. Secondary outcomes included screening rates for HAV and HBV, HCV treatment completion, sustained virologic response (SVR), and specialty pharmacy prescription retention. Logistic regression was performed to assess the relationship between vaccination rates and type of care received (traditional care vs MMC), adjusting for baseline demographic and clinical factors, including, age, sex, HCV genotype, and fibrosis stage. Adjusted odds ratios (aORs) with 95% CIs were calculated for HAV and HBV initiation.
resultsThe study included 330 MMC patients and 250 traditional care patients. Among eligible patients, HAV vaccination rates were higher in the MMC group (33.3% vs 22.6%,
conclusionsIn a setting where HAV and HBV vaccination guidelines remained consistent over time, the pharmacist-led MMC model was associated with higher vaccination and screening rates compared with the traditional care model, and these associations remained robust after adjustment for age, sex, genotype, and fibrosis stage. The model may have contributed to increased treatment initiation during a period of evolving HCV treatment guidelines. These findings support the potential value of pharmacist-led collaborative care agreements in delivering comprehensive HCV management during a period of evolving HCV treatment guidelines. These findings support the potential value of pharmacist-led collaborative care agreements in delivering comprehensive HCV management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.